<DOC>
	<DOCNO>NCT01366118</DOCNO>
	<brief_summary>The parameter best correlate 5 year disease-free survival ( DFS ) patient ( pt ) localize rectal cancer ( RC ) pathological TNM staging ( ypTNM ) chemo-radiotherapy ( Ch-RT ) . DFS 97 % pt ypT0N0M0 = ypCR 42 % pt ypN + . Standard 5-FU Ch-RT achieve 15 % ypCR . The use IMRT achieve high proportion ypCR . This study aim demonstrate prospective manner feasibility personalize Ch regimen base TT combination IMRT patient RC . Secondary objective include number ypCR safety .</brief_summary>
	<brief_title>Study Therapeutic Targets Tailored Ch IMRT Neoadjuvant Treatment Rectal Carcinoma Patients</brief_title>
	<detailed_description>The parameter best correlate DFS patient ( pt ) localize rectal cancer ( RC ) pathological TNM staging ( ypTNM ) chemo-radiotherapy ( Ch-RT ) .Tumor regression grading ( TRG ) Ch-RT correlate DFS , 86 % TRG 4 , 75 % group TRG 2 + 3 , 63 % group TRG 0 + 1 good ypTNM predict pts outcome . Standard 5-FU capecitabine Ch-RT achieve 15 % ypCR diarrhea proctitis main grade 3 toxicity range 10-15 % . With combination oxaliplatin capecitabine pCR rate toxicity range 25 % . IMRT study report 30 % ypCR 30-40 % grade 3 toxicity Last year strategy explore way integrate additional chemotherapeutic agent capecitabine , oxaliplatin , irinotecan , bevacizumab cetuximab Ch-RT regimens find biomarkers effectiveness , always retrospective way . Our hypothesis actual knowledge technology , prospective tailor chemotherapy selection combination IMRT feasible could improve outcome patient rectal cancer .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologic diagnosis rectal adenocarcinoma . Clinical stage II III . Feasible patient neoadjuvant ChRT . Availability tumor tissue possibility tumor biopsy define therapeutic target . Informed write consent obtain patient Contraindication administration drug use study capecitabine , irinotecan , oxaliplatin , cetuximab bevacizumab .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Rectal cancer , Chemoradiotherapy , target therapy</keyword>
</DOC>